Archives of Medical Science · Oct 21, 2026
Shared genetic architecture and mendelian randomisation between simvastatin-related medication use and cholelithiasis: a multi-method GWAS-based analysis
By Feng D, Tong X, Wang Z et al.
Introduction: Statins are widely prescribed, but their relationship with cholelithiasis (CL) remains uncertain. We evaluated shared genetic architecture and MR associations between CL and UK Biobank medication-use phenotypes for simvastatin (SIM) and cholesterol-lowering medication (LLA). Material and methods: GWAS summary statistics were analysed using LDSC, Genomic SEM, MAGMA, univariable MR, lipid-adjusted multivariable MR (MVMR), and cis-drug-target MR for HMGCR, NPC1L1, and PCSK9. MVMR adjusted SIM and LLA separately for LDL-C, HDL-C, and triglycerides. Results: CL showed inverse genetic correlations with SIM (rg = –0.277, p = 1.54 × 10–4) and LLA (rg = –0.223, p = 2.47 × 10–3). Gene and pathway analyses implicated cholesterol–bile acid metabolism and enterohepatic signalling. On the native linear-model outcome scale, univariable MR supported an inverse SIM association ( = –0.050, 95% CI: –0.077 to –0.023, p < 0.001), whereas LLA was not significant (β = –0.029, 95% CI: –0.062 to 0.004, p = 0.090). MVMR direct effects were near null for SIM (β = 0.0051, p = 0.858) and LLA (β = 0.0060, p = 0.631), with conditional F-statistics < 10 and marked heterogeneity. Cis-drug-target MR showed no clear association for HMGCR, NPC1L1, or PCSK9. Conclusions: Genetic liability to simvastatin medication use was modestly inversely associated with CL in univariable MR but not after lipid adjustment. Together, these findings support a potential protective genetic relationship between simvastatin-related medication use and CL and highlight lipid-related and target-specific mechanisms for further mechanistic and clinical validation.